More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

X Biopharma Ltd. (SG:42C) has released an update. iX Biopharma Ltd. announced that its novel semaglutide sublingual wafer, iXB 401, achieved 20 ...

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

The Ipsos survey of 1,078 adults found 24% of people would use weight-loss jabs if they were provided for free by the health ...

Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new British ...

The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

The FDA’s decision to allow the compounding of GLP-1 weight loss drugs could undermine its public health obligations, writes ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...